North America Prescription Digital Therapeutics (PDTx) Market – Industry Trends and Forecast to 2030

Inhaltsverzeichnis anfordernInhaltsverzeichnis anfordern Mit Analyst sprechen Mit Analyst sprechen Jetzt kaufenJetzt kaufen Vor dem Kauf anfragen Vorher anfragen Kostenloser Beispielbericht Kostenloser Beispielbericht

North America Prescription Digital Therapeutics (PDTx) Market – Industry Trends and Forecast to 2030

  • Pharmaceutical
  • Upcoming Reports
  • Feb 2023
  • North America
  • 350 Seiten
  • Anzahl der Tabellen: 220
  • Anzahl der Abbildungen: 60

North America Prescription Digital Therapeutics (PDTx) Market, By Mechanism (Input Mechanisms, Output Mechanisms), Category (Medication Augmentation, Medication Replacement), Treatment (Outpatient Treatment, Monotherapy), Software (Software For Respiratory Conditions, Software For Mental Health, Software For Opioid Use Disorder, Software For Diabetes, Others), Services (Behavioral Microservices, Medical Microservices), App Accessibility (Android, iOS, Windows), App Type (Native Apps, Web Apps), Application (Substance Use Disorder (SUD), Opioid Use Disorder (OUD), Attention Deficit/Hyperactivity Disorder (ADHD), Alzheimer’s Disease, Major Depressive Disorder (MDD), Insomnia, Epilepsy, Movement Disorder, Multiple Sclerosis, Migraine, Autism Spectrum Disorder, Oncology, Inflammation, Respiratory, Cardiovascular, Pain Management, Metabolic Conditions, Others), Patients (Children, Adults) – Industry Trends and Forecast to 2030.

North America Prescription Digital Therapeutics (PDTx) Market

North America Prescription Digital Therapeutics (PDTx) Market Analysis and Size

Growing smartphone penetration in developed & developing countries is inculcating the adoption of prescription digital therapeutics (PDTx). It is developed as a boon for a number of diseases such as ADHD, major depressive disorder (MDD), opioid use disorder (OUD), substance use disorder (SUD), autism spectrum disorder, multiple sclerosis, and cardiovascular disease. According to National Center for Chronic Disease Prevention and Health Promotion, 6 in 10 American adults suffer from a chronic disease, whereas 4 out of 10 adults have 2 or more chronic diseases. Currently, numerous research & clinical studies are going on which is anticipated to create a competitive advantage for numerous manufacturers to develop new and innovative technology.

Data Bridge Market Research analyses a growth rate in the prescription digital therapeutics (PDTx) market in the forecast period 2023-2030. The expected CAGR of prescription digital therapeutics (PDTx) market is tend to be around 22% in the mentioned forecast period. The market is valued at USD 751.58 million in 2022, and it would grow upto USD 3688.53 million by 2030. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

North America Prescription Digital Therapeutics (PDTx) Market Scope and Segmentation

Report Metric

Details

Forecast Period

2023 to 2030

Base Year

2022

Historic Years

2021 (Customizable to 2015 - 2020)

Quantitative Units

Revenue in USD Million, Volumes in Units, Pricing in USD

Segments Covered

Mechanism (Input Mechanisms, Output Mechanisms), Category (Medication Augmentation, Medication Replacement), Treatment (Outpatient Treatment, Monotherapy), Software (Software For Respiratory Conditions, Software For Mental Health, Software For Opioid Use Disorder, Software For Diabetes, Others), Services (Behavioral Microservices, Medical Microservices), App Accessibility (Android, iOS, Windows), App Type (Native Apps, Web Apps), Application (Substance Use Disorder (SUD), Opioid Use Disorder (OUD), Attention Deficit/Hyperactivity Disorder (ADHD), Alzheimer’s Disease, Major Depressive Disorder (MDD), Insomnia, Epilepsy, Movement Disorder, Multiple Sclerosis, Migraine, Autism Spectrum Disorder, Oncology, Inflammation, Respiratory, Cardiovascular, Pain Management, Metabolic Conditions, Others), Patients (Children, Adults)

Countries Covered

U.S., Canada and Mexico in North America

Market Players Covered

ResMed (U.S.), SAMSUNGHEALTHCARE (South Korea), Biofourmis (U.S.), Novartis AG (Switzerland), Medtronic (Ireland), Pear Therapeutics, Inc. (U.S.), Voluntis (France), Omada Health, Inc. (U.S.), GAIA AG (Germany), Welldoc’s Bluestar (U.S.), Solera Network (U.S.), Akili Interactive Labs, Inc. (U.S.), Better Therapeutics, LLC (U.S.), BigHealth (U.S.), Biofourmis (U.S.), Click Therapeutics, Inc. (U.S.), Happify, Inc. (U.S.), Limbix Health, Inc. (U.S.), Naturalcycles Nordic AB (Sweden), NuvoAir AB (Sweden), Sensyne Health plc. (U.K.), Xealth (U.S.)

Market Opportunities

  • Increased Research Activities
  • Increased Mergers and Acquisitions

Market Definition

Prescription digital therapies is a kind of software that is used to treat numerous ailments. Artificial intelligence, diverse algorithms, and virtual reality are widely used to develop these therapeutic instruments. Patients sometimes use prescription digital therapeutics software and services to get any form of treatment they needed it. These medicines are closely regulated by the FDA and other regulatory authorities and can only be used with an appropriate prescription from a doctor.

North America Prescription Digital Therapeutics (PDTx) Market Dynamics

Drivers

  • Increasing Regulatory Initiatives

Rising regulatory initiatives are estimated to boost standardization and R&D in the market during the forecast period. For instance, the Software Pre-Cert Pilot Program which is a part of the Digital Health Innovation Action Plan of the FDA, planned for a more efficient regulatory oversight of Software-based Medical Devices (SaMD) developed by manufacturers. The main aim is to develop an efficient regulatory oversight for evaluating organizations to establish trust that they can develop high-quality SaMD products. Therefore, this factor increases the growth of the market.

  • Huge Role in Managing Respiratory Diseases

The increasing adoption of digital therapeutic products for managing respiratory diseases is boosting the market growth. These products include BreatheSmart by Cohero Health, Respiro by Amiko, Propeller by Propeller Health, Hailie by Adherium, and CareTRx by Teva. Digital therapeutics helps to transform the treatment course of COPD and asthma as poor medication adherence is a big issue for treating respiratory diseases. Digital therapeutic solutions can help a lot in this regard. This factor improves the market growth.

Opportunities

  • Increased Research Activities

The research activities associated with the prescription digital therapeutics is increasing and thus boosting the market's growth. For instance, NuvoAir AB was certified as Class Im medical device in August 2020. The company has achieved this certification due to its advanced features involving certified bluetooth spirometer, combined with the healthcare portal and connected patient app. This certification has improved the brand value among the physicians and patients. Thus, this factor created much opportunity for the market growth.

  • Increased Mergers and Acquisitions

The number of mergers and acquisitions has grown in the recent years which is increasing the market growth. For instance, Teladoc expanded its partnership with the National Labor Alliance in December 2021 for providing its full suite of virtual care products and services. It includes general medical, expert medical services, specialty care, virtual primary care programs, mental health, and chronic condition management. Thus, this factor helps in the market expansion.  

Restraints/Challenges

  • Difficulty in Adaptation of Digital Therapeutics by Doctors

Not all doctors and providers are not familiar with the increasing digitization. Doctors and healthcare professionals should get familiar with digital therapy solutions before using their mass adoption. They should analyze the results of clinical trials before recommending the solutions to their patients. To perform this, few DTx companies opt for pharmaceutical model wherein partnerships with distributors are used to inform doctors about clinical trial results, new solutions, and decisions. Thus, this hampers the market growth.

This prescription digital therapeutics (PDTx) market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the prescription digital therapeutics (PDTx) market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Recent Development

  • In 2019, Welldoc Inc., announces the development and commercialization of BlueStar to East Asia with Japan based Astellas Inc. Under the agreement, Astellas and Welldoc will jointly develop and commercialize BlueStar in Japan and certain other Asian markets for patients with diabetes, collaborate to widen the adoption of BlueStar. 

North America Prescription Digital Therapeutics (PDTx) Market Scope

The prescription digital therapeutics (PDTx) market is segmented on the basis of mechanism, category, treatment, software, services, app accessibility, app type, application, patients. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Mechanism

  • Input Mechanisms
  • Output Mechanisms

Category

  • Medication Augmentation
  • Medication Replacement

Treatment

  • Outpatient Treatment
  • Monotherapy

Software

  • Software for Respiratory Conditions
  • Software for Mental Health
  • Software for Opioid Use Disorder
  • Software for Diabetes
  • Others

Services

  • Behavioral Microservices
  • Medical Microservices

App Accessibility

  • Android
  • iOS
  • Windows

App Type

  • Native Apps
  • Web Apps

Application

  • Substance Use Disorder (SUD)
  • Opioid Use Disorder (OUD)
  • Attention Deficit/Hyperactivity Disorder (ADHD)
  • Alzheimer’s Disease
  • Major Depressive Disorder (MDD)
  • Insomnia
  • Epilepsy
  • Movement Disorder
  • Multiple Sclerosis
  • Migraine
  • Autism Spectrum Disorder
  • Oncology
  • Inflammation
  • Respiratory
  • Cardiovascular
  • Pain Management
  • Metabolic Conditions
  • Others

Patients

  • Children
  • Adults

Prescription Digital Therapeutics (PDTx) Market Regional Analysis/Insights

The prescription digital therapeutics (PDTx) market is analyzed and market size insights and trends are provided by mechanism, category, treatment, software, services, app accessibility, app type, application, patients as referenced above.

The major countries covered in the prescription digital therapeutics (PDTx) market report are U.S., Canada and Mexico in North America.

U.S. is anticipated to grow with the highest CAGR in the forecast period due to the increased adoption of prescription digital therapeutics (PDTx) by the patients in this region. Also, increased presence of major market players in the region and the launch of multiple products boosts the market growth.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Also, the presence and availability of North America brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.   

Competitive Landscape and North America Prescription Digital Therapeutics (PDTx) Market Share Analysis

The prescription digital therapeutics (PDTx) market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, North America presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to prescription digital therapeutics (PDTx) market.

Key players operating in the prescription digital therapeutics (PDTx) market include:

  • ResMed (U.S.)
  • SAMSUNGHEALTHCARE (South Korea)
  • Biofourmis (U.S.)
  • Novartis AG (Switzerland)
  • Medtronic (Ireland)
  • Pear Therapeutics, Inc. (U.S.)
  • Voluntis (France)
  • Omada Health, Inc. (U.S.)
  • GAIA AG (Germany)
  • Welldoc’s Bluestar (U.S.)
  • Solera Network (U.S.)
  • Akili Interactive Labs, Inc. (U.S.)
  • Better Therapeutics, LLC (U.S.)
  • BigHealth (U.S.)
  • Biofourmis (U.S.)
  • Click Therapeutics, Inc. (U.S.)
  • Happify, Inc. (U.S.)
  • Limbix Health, Inc. (U.S.)
  • Naturalcycles Nordic AB (Sweden)
  • NuvoAir AB (Sweden)
  • Sensyne Health plc. (U.K.)
  • Xealth (U.S.)


SKU-

Erhalten Sie Online-Zugriff auf den Bericht zur weltweit ersten Market Intelligence Cloud

  • Interaktives Datenanalyse-Dashboard
  • Unternehmensanalyse-Dashboard für Chancen mit hohem Wachstumspotenzial
  • Zugriff für Research-Analysten für Anpassungen und Abfragen
  • Konkurrenzanalyse mit interaktivem Dashboard
  • Aktuelle Nachrichten, Updates und Trendanalyse
  • Nutzen Sie die Leistungsfähigkeit der Benchmark-Analyse für eine umfassende Konkurrenzverfolgung
Demo anfordern

Forschungsmethodik

Die Datenerfassung und Basisjahresanalyse werden mithilfe von Datenerfassungsmodulen mit großen Stichprobengrößen durchgeführt. Die Phase umfasst das Erhalten von Marktinformationen oder verwandten Daten aus verschiedenen Quellen und Strategien. Sie umfasst die Prüfung und Planung aller aus der Vergangenheit im Voraus erfassten Daten. Sie umfasst auch die Prüfung von Informationsinkonsistenzen, die in verschiedenen Informationsquellen auftreten. Die Marktdaten werden mithilfe von marktstatistischen und kohärenten Modellen analysiert und geschätzt. Darüber hinaus sind Marktanteilsanalyse und Schlüsseltrendanalyse die wichtigsten Erfolgsfaktoren im Marktbericht. Um mehr zu erfahren, fordern Sie bitte einen Analystenanruf an oder geben Sie Ihre Anfrage ein.

Die wichtigste Forschungsmethodik, die vom DBMR-Forschungsteam verwendet wird, ist die Datentriangulation, die Data Mining, die Analyse der Auswirkungen von Datenvariablen auf den Markt und die primäre (Branchenexperten-)Validierung umfasst. Zu den Datenmodellen gehören ein Lieferantenpositionierungsraster, eine Marktzeitlinienanalyse, ein Marktüberblick und -leitfaden, ein Firmenpositionierungsraster, eine Patentanalyse, eine Preisanalyse, eine Firmenmarktanteilsanalyse, Messstandards, eine globale versus eine regionale und Lieferantenanteilsanalyse. Um mehr über die Forschungsmethodik zu erfahren, senden Sie eine Anfrage an unsere Branchenexperten.

Anpassung möglich

Data Bridge Market Research ist ein führendes Unternehmen in der fortgeschrittenen formativen Forschung. Wir sind stolz darauf, unseren bestehenden und neuen Kunden Daten und Analysen zu bieten, die zu ihren Zielen passen. Der Bericht kann angepasst werden, um Preistrendanalysen von Zielmarken, Marktverständnis für zusätzliche Länder (fordern Sie die Länderliste an), Daten zu klinischen Studienergebnissen, Literaturübersicht, Analysen des Marktes für aufgearbeitete Produkte und Produktbasis einzuschließen. Marktanalysen von Zielkonkurrenten können von technologiebasierten Analysen bis hin zu Marktportfoliostrategien analysiert werden. Wir können so viele Wettbewerber hinzufügen, wie Sie Daten in dem von Ihnen gewünschten Format und Datenstil benötigen. Unser Analystenteam kann Ihnen auch Daten in groben Excel-Rohdateien und Pivot-Tabellen (Fact Book) bereitstellen oder Sie bei der Erstellung von Präsentationen aus den im Bericht verfügbaren Datensätzen unterstützen.

Häufig gestellte Fragen

The North America Prescription Digital Therapeutics (PDTx) Market is projected to grow at a CAGR of 22.0% during the forecast period by 2030.
The future market value of the North America Prescription Digital Therapeutics (PDTx) Market is expected to reach USD 3688.53 million by 2030.
The major players in the North America Prescription Digital Therapeutics (PDTx) Market are ResMed (U.S.), SAMSUNGHEALTHCARE (South Korea), Biofourmis (U.S.), Novartis AG (Switzerland), Medtronic (Ireland), Pear Therapeutics, Inc. (U.S.), Voluntis (France), Omada Health, Inc. (U.S.), etc.
The countries covered in the North America Prescription Digital Therapeutics (PDTx) Market are U.S., Canada and Mexico in North America.